Trial Profile
A Phase 4, Multicenter, Randomized, Double-blind, Parallel-group, Comparative Study to Evaluate the Efficacy and Safety of AD-4833 When Orally Administered Once Daily as add-on to SYR-322 Versus SYR-322 Alone in the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control Despite Treatment With SYR-322 in Addition to Diet and/or Exercise Therapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Sep 2023
Price :
$35
*
At a glance
- Drugs Alogliptin (Primary) ; Pioglitazone (Primary)
- Indications Diabetes mellitus
- Focus Therapeutic Use
- Sponsors Takeda
- 19 May 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 24 Sep 2012 New trial record
- 01 Sep 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.